The full menu of approved options
From injectable GLP-1 and dual agonists to oral combinations and a lipase inhibitor, the FDA-approved arsenal now spans a wide efficacy range — roughly 2.4% to 20.9% placebo-adjusted weight loss. The right choice depends on your biology, your tolerance, and your goals. This table lays out the entire landscape. Most people who read this are comparing BMI calculator for weight loss medication options around Grand Rapids, MI, so what follows sticks to the details that change in practice.
| Generic Name | Trade Name(s) | Receptor Targets & Class | FDA Status | Placebo-Adjusted Weight Loss Efficacy | Primary Biological Action | Source |
|---|---|---|---|---|---|---|
| Tirzepatide | Zepbound (weight loss), Mounjaro (diabetes) | Dual GLP-1 and GIP receptor agonist | Chronic weight management (FDA-approved 2023) | 17.8%–20.9% (at 15 mg dose) | Slowing gastric emptying, increasing satiety, and improving glycemic control via dual-action central signaling | 2, Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Semaglutide | Wegovy (weight loss), Ozempic (diabetes) | Selective GLP-1 receptor agonist | Chronic weight management (FDA-approved 2021) | 12.0%–12.4% | Slowing gastric emptying and central appetite suppression via the hypothalamus to reduce cravings | 3, 2, Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Phentermine/topiramate | Qsymia | Substituted amphetamine (Sympathomimetic amine) / GABA modulator & carbonic anhydrase inhibitor | Chronic weight management (also indicated for short-term) | 8.8%–10.2% | Appetite suppression via norepinephrine release and increased satiety via neurotransmitter modification | Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Liraglutide | Saxenda (weight loss), Victoza (diabetes) | Selective GLP-1 receptor agonist | Chronic weight management | 4.0%–5.4% | Regulation of appetite and calorie intake by slowing gastric emptying and increasing feelings of fullness | Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Naltrexone/bupropion | Contrave | Opioid antagonist / Norepinephrine-dopamine reuptake inhibitor (NDRI) | Chronic weight management | 4.0%–5.0% | Targets the reward system (mesolimbic) and hypothalamus to reduce food cravings and appetite | Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Phentermine | Adipex-P, Lomaira | Substituted amphetamine (Sympathomimetic amine; TAAR1 agonist) | Short-term use (up to 12 weeks) | 3.0%–4.0% (or ~5 kg / 11 lb) | Stimulation of norepinephrine release to suppress appetite | Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Orlistat | Xenical (Prescription), Alli (OTC) | Gastric and pancreatic lipase inhibitor (Non-receptor) | Chronic weight management | 2.4%–4.0% (or ~3 kg / 6.6 lb) | Inhibition of gastrointestinal lipases to prevent the absorption of dietary fat in the intestines | 3, Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Sibutramine | Meridia | Not in source | Withdrawn | Not in source | Appetite suppression |
Reading the table
Efficacy climbs with receptor coverage: selective GLP-1 (Wegovy) hits ~12%, the dual GLP-1/GIP agonist tirzepatide (Zepbound) reaches ~18–21% at the top dose, and oral/combination options (Qsymia, Contrave) occupy the 4–10% band with a different side-effect profile. Lower efficacy is not worse — it is often the right trade for someone who tolerates oral meds or needs short-term support.
The short version
- The article reports that FDA-approved weight-loss medications span a placebo-adjusted weight-loss range from roughly 2.4% to as high as 20.9%.
- Tirzepatide, sold as Zepbound for weight loss and Mounjaro for diabetes, is a dual GLP-1 and GIP receptor agonist approved in 2023 and listed at 17.8% to 20.9% at the 15 mg dose.
- Semaglutide, sold as Wegovy and Ozempic, is a selective GLP-1 receptor agonist approved in 2021 and listed at 12.0% to 12.4%.
- Phentermine/topiramate (Qsymia) is given as 8.8% to 10.2%, liraglutide (Saxenda) at 4.0% to 5.4%, and naltrexone/bupropion (Contrave) at 4.0% to 5.0%.
- Phentermine (Adipex-P) is approved only for short-term use up to 12 weeks at 3.0% to 4.0%, and orlistat (Xenical, Alli) inhibits gastrointestinal lipases at 2.4% to 4.0%.
- Sibutramine (Meridia) is listed as withdrawn, and the article notes efficacy climbs with receptor coverage while oral and combination options occupy the 4-10% band.
Choose with a provider, not a comment section
Every option in this table is a prescription for a reason. Get matched with a local weight-loss provider who can match your profile to the right class — free, no obligation.
